CPT code 47383 represents percutaneous cryosurgical ablation of one or more liver tumors, a minimally invasive technique that freezes tumor tissue to achieve local control. This code is clinically significant as percutaneous tumor ablation is an important alternative or adjunct to surgical resection and thermal ablation methods for selected patients with primary or metastatic liver lesions. Nationally, utilization intersects oncology, interventional radiology, and outpatient procedural care pathways, affecting payer coverage and authorization workflows.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and typical service settings, payer coverage considerations, and common billing modifiers associated with procedural variations. The publication provides benchmarks where available, summaries of relevant policy updates that influence coverage and site-of-service decisions, and practical billing considerations such as documentation elements that support medical necessity for percutaneous cryoablation.

The content is intended for revenue cycle professionals, interventional radiologists, surgical oncologists, and policy analysts seeking a national-level reference for coding and payer interactions related to percutaneous liver cryoablation under CPT code 47383. Data not available in the input will be noted where applicable.